Understanding OUR Cytokine-Based Immunotherapy Candidates Our Commitment extends to advancing a robust portfolio of programs aimed at expanding the horizons of cytokine-based immunotherapy, specifically for cancers where therapy alternatives remain limited. Use the links below to learn additional about our portfolio of cytokine-based immunotherapy candidates. Take a look at https://financefeeds.com/nasdaq-plans-24-hour-trading-by-2026-to-meet-global-demand/